CLOSE

Thoracic Oncology

highlight

A close collaboration with the Division of Thoracic Surgery and Radiotherapy make sure the correct follow-up of the patient from the pre- to the postsurgical time.  

Our Activities

The Division was established to guarantee the best of care to patients with thoracic malignancies; a dedicated staff takes care of the patient in each stage of disease. The clinical practice of the Division consists of in- and outpatients treatment, according to the complexity of the therapy, and of consultations for second opinions.

The principal fields of interest of the Division of Thoraric Oncology include phase 2 and phase 3 trial on non-small-cell lung cancer with EGFR mutations and ALK translocation in first, second and other lines of treatment. In addition, at the present time,  we have different available clinical trial evaluating target agents against MET, ROS1, HER2,  and BRAF over the first-line setting.  In addiction to the development of the previous discussed target agents, in this latter period we are able to enrolled patients in multiple and extremely promising clinical trial for advanced, adjuvant and neo-adjuvant setting using immune check-point inhibitor as anti-PD1 and PD-L1 drug,  in squamous and adenocarcinoma of the lung

In this year, the Division of Thoracic Oncology treated about 600 patients with lung cancer, in neo-adjuvant setting to improve results or a sequent surgery; in adjuvant, after surgery to improve outcome and minimize recurrence of disease. Patients with locally advanced disease were treated with a concomitant radiation therapy and chemotherapy.

Every single patients was treated based on a multidisciplinary approach, that improve results and maximize adherence to proposed treatment. Patients with metastatic setting benefit of different kind of treatment with chemotherapy, target agents or immune check point inhibitor, managed from physicians with a high grade of experience.

The Division of Thoracic Oncology is not only a corner stone for patients with non-small-cell lung cancer, but also for patients with neuroendocrine tumors of the lung and mesothelioma, that could benefit of a trimodality approach with chemotherapy, radiation therapy and surgery.  

The Division of Thoracic Oncology is devoted to improve survival and quality of life of every patients with lung cancer treated at IEO. 

 

  • Our staff
     

    Thoracic Oncology

    Director

    Filippo de Marinis

    Staff Thoracic Oncology

  • research activities

    Clinical research activity.

    The Division gives the opportunity to participate to appropriate clinical trials; the novel drugs and therapies currently under study vary among targeted therapy (the drugs target specific proteins of pivotal pathways altered in NSCLC), combined therapy and immunotherapy.

     

    Basic research activity.

    A long and successful collaboration with Italian and foreign researchers led to the publication on international peer-review journals of several studies, including
    those dealing with pharmacogenomics/genetics and with low grade neuroendocrine tumor of the lung; now the research program is focused on whole genome sequencing of lung adenocarcinomas and on the activity of molecular drugs in specific subsets of patient.

     

     

PARTNERSHIP

Università degli Studi di Milano Ecancer Medical Science IFOM-IEO Campus

CREDITS

Ministero della Salute Joint Commission International Breastcertification bollinirosa

© 2013 Istituto Europeo di Oncologia - via Ripamonti 435 Milano - P.I. 08691440153

IRCCS - ISTITUTO DI RICOVERO E CURA A CARATTERE SCIENTIFICO

facebook IEO googleplus IEO twitter IEO pinterest IEO vimeo IEO